Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Craig Haifer

Showing results (11-20 of 27) with videos related to

Pageof 3
Sort By:
Msystems|August 13, 2024
Refining microbial community metabolic models derived from metagenomics using reference-based taxonomic profilingMarwan E Majzoub, Laurence D W Luu, Craig Haifer, et al.
Msystems|September 15, 2025
Bacterial taxonomic and functional changes following oral lyophilized donor fecal microbiota transplantation in patients with ulcerative colitisShreeya S Raich, Marwan E Majzoub, Craig Haifer, et al.
Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society|July 22, 2015
Targeted individual prophylaxis offers superior risk stratification for cytomegalovirus reactivation after liver transplantationSiddharth Sood, Craig Haifer, Lijia Yu, et al.
The Lancet. Gastroenterology & Hepatology|December 5, 2021
Lyophilised oral faecal microbiota transplantation for ulcerative colitis (LOTUS): a randomised, double-blind, placebo-controlled trialCraig Haifer, Sudarshan Paramsothy, Nadeem O Kaakoush, et al.
Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society|January 31, 2017
A novel immune function biomarker identifies patients at risk of clinical events early following liver transplantationSiddharth Sood, Craig Haifer, Lijia Yu, et al.
Journal of Gastroenterology and Hepatology|February 28, 2025
Comparing Long-Term Infliximab Persistence Following a Switch to a Biosimilar in Patients With Inflammatory Bowel Disease: No Cause for ConcernPaulina Suo, Ashish Srinivasan, Lena Thin, et al.
BMC Cancer|April 11, 2025
A study protocol for a double-blinded, randomised, placebo-controlled trial on the use of encapsulated FMT for reducing the side effects of HSCT: the HSCT-BIOME studyAnna Li, Sam P Costello, Robert V Bryant, et al.
Gut|April 29, 2025
Translational strategies for oral delivery of faecal microbiota transplantationSrinivas Kamath, Robert V Bryant, Samuel P Costello, et al.
European Journal of Gastroenterology & Hepatology|May 5, 2018
Entyvio lengthen dose-interval study: lengthening vedolizumab dose interval and the risk of clinical relapse in inflammatory bowel diseaseWebber Chan, Nicole Lynch, Peter Bampton, et al.
Journal of Gastroenterology and Hepatology|October 10, 2025
IBD 2024: Charting a New Course in IBD Proceedings of the Takeda Symposium 22-23 November 2024 W Hotel, Brisbane, Queensland, AustraliaUma Mahadevan, Vipul Jairath, Jakob Begun, et al.
Pageof 3

Showing results (11-20 of 27) with videos related to

Sort By:
Pageof 3
Msystems|August 13, 2024
Refining microbial community metabolic models derived from metagenomics using reference-based taxonomic profilingMarwan E Majzoub, Laurence D W Luu, Craig Haifer, et al.
Msystems|September 15, 2025
Bacterial taxonomic and functional changes following oral lyophilized donor fecal microbiota transplantation in patients with ulcerative colitisShreeya S Raich, Marwan E Majzoub, Craig Haifer, et al.
Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society|July 22, 2015
Targeted individual prophylaxis offers superior risk stratification for cytomegalovirus reactivation after liver transplantationSiddharth Sood, Craig Haifer, Lijia Yu, et al.
The Lancet. Gastroenterology & Hepatology|December 5, 2021
Lyophilised oral faecal microbiota transplantation for ulcerative colitis (LOTUS): a randomised, double-blind, placebo-controlled trialCraig Haifer, Sudarshan Paramsothy, Nadeem O Kaakoush, et al.
Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society|January 31, 2017
A novel immune function biomarker identifies patients at risk of clinical events early following liver transplantationSiddharth Sood, Craig Haifer, Lijia Yu, et al.
Journal of Gastroenterology and Hepatology|February 28, 2025
Comparing Long-Term Infliximab Persistence Following a Switch to a Biosimilar in Patients With Inflammatory Bowel Disease: No Cause for ConcernPaulina Suo, Ashish Srinivasan, Lena Thin, et al.
BMC Cancer|April 11, 2025
A study protocol for a double-blinded, randomised, placebo-controlled trial on the use of encapsulated FMT for reducing the side effects of HSCT: the HSCT-BIOME studyAnna Li, Sam P Costello, Robert V Bryant, et al.
Gut|April 29, 2025
Translational strategies for oral delivery of faecal microbiota transplantationSrinivas Kamath, Robert V Bryant, Samuel P Costello, et al.
European Journal of Gastroenterology & Hepatology|May 5, 2018
Entyvio lengthen dose-interval study: lengthening vedolizumab dose interval and the risk of clinical relapse in inflammatory bowel diseaseWebber Chan, Nicole Lynch, Peter Bampton, et al.
Journal of Gastroenterology and Hepatology|October 10, 2025
IBD 2024: Charting a New Course in IBD Proceedings of the Takeda Symposium 22-23 November 2024 W Hotel, Brisbane, Queensland, AustraliaUma Mahadevan, Vipul Jairath, Jakob Begun, et al.
Pageof 3